Acute fascioliasis-clinical and epidemiological features of four patients in Chile

Clinical Microbiology and Infection

Volumn 18, Issue 1, 2012, Pages 91-96

  Fica, A ^a   Dabanch, J ^a   Farias, C ^a   Castro, M ^a   Jercic, M I ^b   Weitzel, T ^a,c,d  

^a HOSPITAL MILITAR DE SANTIAGO   (Chile)

^b INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^c UNIVERSIDAD DE VALPARAÍSO   (Chile)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute phase; Diagnosis; Fasciola hepatica; Human fascioliasis; Portal vein thrombosis; Treatment

Indexed keywords

TRICLABENDAZOLE;

ADULT; ARTICLE; CASE REPORT; CHILE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EOSINOPHILIA; FASCIOLIASIS; FEMALE; FEVER; HUMAN; LIVER INJURY; MALE; NAUSEA AND VOMITING; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; UPPER ABDOMINAL PAIN; URBAN AREA; WATERCRESS;

FASCIOLA HEPATICA; NASTURTIUM OFFICINALE; PROTEA; TREMATODA;

EID: 83655201481     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03575.x     Document Type: Article

References (26)

1. Mas-Coma S. Human fascioliasis. In: Cotruvo JA, Dufour A, Rees G, Bartram J, Carr R, Cliver DO, Craun GF, Fayer R, Gannon VPJ, eds. Waterborne zoonoses: identification, causes and control. London: IWA Publishing, 2004; 305-322.
2. World Health Organization. Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control. Geneva: WHO, 2007.
3. Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev 2009; 22: 466-483.
4. Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33: 1-5.
5. Noyer CM, Coyle CM, Werner C, Dupouy-Camet J, Tanowitz HB, Wittner M. Hypereosinophilia and liver mass in an immigrant. Am J Trop Med Hyg 2002; 66: 774-776.
6. Kang ML, Teo CH, Wansaicheong GK, Giron DM, Wilder-Smith A. Fasciola hepatica in a New Zealander traveler. J Travel Med 2008; 15: 196-199.
7. Chand MA, Herman JS, Partridge DG, Hewitt K, Chiodini PL. Imported human fascioliasis, United Kingdom. Emerg Infect Dis 2009; 15: 1876-1877.
8. Arjona R, Riancho JA, Aguado JM, Salesa R, González-Marcías J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore) 1995; 74: 13-23.
9. Aksoy DY, Kerimoglu U, Oto A et al Infection with Fasciola hepatica. Clin Microbiol Infect 2005; 11: 859-861.
10. Marcos LA, Tagle M, Terashima A et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008; 78: 222-227.
11. MacLean JD, Cross J, Mahanty S. Liver, lung and intestinal fluke infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens & practise, 2nd edn. Philadelphia, PA: Churchill Livingston Elsevier, 2005; 1349-1369.
12. Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fasciolasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008; 21: 523-530.
13. Behar JM, Winston JS, Borgstein R. Hepatic fascioliasis at a London hospital-the importance of recognising typical radiological features to avoid a delay in diagnosis. Br J Radiol 2009; 82: e189-e193.
14. Cerri GG, Alves VA, Magalhães A. Hepatosplenic Schistosomiasis mansoni: ultrasound manifestations. Radiology 1984; 153: 777-780.
15. Agarwal N, Kumar S. Budd-Chiari syndrome owing to liver hydatid disease: case report and review of the literature. Ann Trop Paediatr 2009; 29: 301-304.
16. Apt W, Aguilera X, Vega F et al. Prevalence of fascioliasis in humans, horses, pigs, and wild rabbits in 3 Chilean provinces. Bol Oficina Sanit Panam 1993; 115: 405-414.
17. Cosme A, Ojeda E, Cilla G et al. Fasciolasis hepatobiliar. Estudio de una serie de 37 pacientes. Gastroenterol Hepatol 2001; 24: 375-380.
18. Hassan MM, Farghaly AM, el-Gamal RL, el-Ridi AM. Cross-reactions in immunodiagnosis of patients infected with Schistosoma, Fasciola and Heterophyes using ELISA. J Egypt Soc Parasitol 1989; 19 (suppl 2): 845-851.
19. Romasanta A, Romero JL, Arias M et al. Diagnosis of parasitic zoonoses by immunoenzymatic assays-analysis of cross-reactivity among the excretory/secretory antigens of Fasciola hepatica, Toxocara canis, and Ascaris suum. Immunol Invest 2003; 32: 131-142.
20. Shehab AY, Basha LM, El-Morshedy HN, Abdel-Fattah M, Osman MM, Farag HF. Circulating antibodies and antigens correlate with egg counts in human fascioliasis. Trop Med Int Health 1999; 4: 691-694.
21. Mailles A, Capek I, Ajana F, Schepens C, Ilef D, Vaillant V. Commercial watercress as an emerging source of fascioliasis in Northern France in 2002: results from an outbreak investigation. Epidemiol Infect 2006; 134: 942-945.
22. Mas-Coma S, Valero MA, Bargues MD. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol 2009; 69: 41-146.
23. Alcaíno H, Vega F, Gorman T. Epidemiología de la fasciolasis hepática en la VII Región Chile. Parasitol Día 1993; 17: 99-106.
24. Apt W, Aguilera X, Vega F et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52: 532-535.
25. Millán JC, Mull R, Freise S, Richter J. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63: 264-269.
26. Jave JA, Alban M, Sapastegui C, Soriano S. Tratamiento de la fasciolasis hepática humana con triclabendazole. Rev Gastroenterol Perú 1999; 19: 216-220.